Merck MRK announced that it is discontinuing the development of two of its cancer candidates, vibostolimab and favezelimab.

Lung cancer is still one of the most common malignancies with a high global mortality rate with over 2 million cases confirmed by the World Health Organization in 2018. Although there has been ...

Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Lung cancer was nowhere on her radar. "We're definitely seeing more and more, not only lung cancer, but really ...

Over a 45-years span — between 1975 and 2020 — improvements in cancer screenings and prevention strategies have reduced ...

Cancer survival estimates in Europe highlight notable geographical and economic disparities. Several factors are driving gaps ...

Affimed (AFMD) stock plunged 23% after the company reported updated data from a clinical trial of AFM24/atezolizumab in the ...

Bobbi Conner talks with MUSC's Dr. Tucker Marrison about cancer screening recommendations for adults, with an update about ...

Puma Biotechnology faces challenges but has a solid financial base. Learn why PBYI stock is a "Buy" with potential upside ...

Background Limited research exists on screening thresholds for low-dose CT in detecting malignant pure ground-glass lung ...

Though lung cancer is still the deadliest cancer, causing 1 in 5 cancer deaths, most eligible for annual lung cancer ...